drugset
drugset / Trial / NCT02003131

Safety and Feasibility Study of Mesenchymal Trophic Factor (MTF) for Treatment of Osteoarthritis

NCT02003131 ↗

Phase 1/2 Withdrawn Translational Biosciences
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Allogeneic mesenchymal trophic factors (MTF) from human umbilical cord tissue-derived mesenchymal stem cells (UC-MSC) injected into the knee joints of 20 patients (group 1) or injected subcutaneously into 20 patients (group 2) is a safe and useful procedure for inducing joint function improvements in osteoarthritis (OA) patients with grade 2, 3, or 4 radiographic OA severity.

Timeline

Start
2013-12
Primary completion
2018-12
Completion
2019-06

Outcome

Outcome not reported

Stopped (Enrollment): “No enrollment”

Drugs

EvaluationDrugModalityDoseRoute
Subject Mesenchymal Trophic Factor Unknown — Other

Indications

osteoarthritis, knee